
    
      This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic
      atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the
      safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.

      Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in
      the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment
      na√Øve subjects that did not participate in the GEM-CL-10301 Study and who meet all
      eligibility criteria will be enrolled.
    
  